In June 2025, mazdutide was approved for the use of weight management and type 2 diabetes (T2D) in China, under the name of Xinermei. This drug was developed by Eli Lilly, a company also responsible for the development of tirzepatide (sold as Mounjaro® and Zepbound®) and dulaglutide (sold as Trulicity®), both of which are very […]








